Cytotoxic Chemotherapy Library Entry

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Topoisomerase Inhibitors DMPK and Bioanalytical Services

Topoisomerase inhibitor bioanalysis must account for different disposition routes within one oncology class. Doxorubicin and epirubicin require CYP / P-gp-aware interpretation, etoposide is driven mainly by CYP3A4-linked Phase I metabolism, and irinotecan depends on CES activation plus UGT1A1-related Phase II clearance.

Creative Proteomics develops LC-MS/MS and DMPK workflows that connect parent-drug quantification with MetID, transporter context, prodrug activation, Phase II metabolism, DDI risk assessment, and custom oncology panel development.

Browse Topoisomerase Inhibitor Drug Index Request Custom Topoisomerase Inhibitor Method Support

Pathway SplitSeparate anthracycline, etoposide, and irinotecan workflows by the dominant DMPK route.

Phase I / Phase II LogicConnect CYP metabolism, CES activation, and UGT1A1 glucuronidation to the analytical readout.

DDI-Aware PanelsIntegrate P-gp context, CYP substrate behavior, MetID, and oncology panel compatibility.

Topoisomerase Inhibitor Study Logic Parent → MetID → Activation / Clearance

🧬

Anthracycline RouteDoxorubicin and epirubicin require CYP2D6 / CYP3A4, P-gp, and Phase I MetID interpretation.

🧫

Etoposide RouteCYP3A4 metabolism and P-gp substrate context guide workflow design.

🔁

Irinotecan ActivationCES activation and UGT1A1 Phase II metabolism require a separate route.

📊

Study-Ready OutputLC-MS/MS data aligned with parent exposure, MetID, activation, DDI risk, and panels.

Pathway-specific bioanalytical design.One workflow can connect parent quantification, CYP metabolism, P-gp context, CES activation, UGT1A1 Phase II metabolism, and oncology panel development.

Topoisomerase Inhibitor Drug Index

Find the Topoisomerase Inhibitor Behind the Study

Use the index to route each topoisomerase inhibitor to the right DMPK question: CYP / P-gp-driven MetID and DDI risk for doxorubicin, epirubicin, and etoposide; CES activation and UGT1A1 Phase II metabolism for irinotecan.

A-Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only topoisomerase inhibitors matching all selected values.

4 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in Topoisomerase Inhibitor Studies?

Topoisomerase inhibitor assays often fail when the compounds are treated as a single cytotoxic category. The main challenge is that this group contains different DMPK logic in one page: anthracycline-type compounds require CYP / P-gp / DDI-aware interpretation, etoposide often follows a CYP3A4 and transporter-associated Phase I route, while irinotecan requires prodrug activation and Phase II clearance analysis.

Anthracyclines Require Integrated CYP and P-gp Interpretation

Doxorubicin and epirubicin may require CYP2D6 / CYP3A4-aware metabolism support and P-gp substrate context. Without transporter-aware interpretation, concentration data may not fully explain exposure shifts or DDI-related behavior.

Our responseAnthracycline workflows that connect parent-drug quantification, CYP-linked metabolism, P-gp substrate context, microsome / hepatocyte data, and DDI risk-oriented reporting.

DDI Studies →

Etoposide Needs CYP3A4 and Transporter-Aware Design

Etoposide is often interpreted through CYP3A4-mediated Phase I metabolism and transporter-associated disposition. A parent-only assay may not answer metabolite formation, clearance, or DDI-related questions.

Our responseCYP3A4-focused metabolism studies, microsome / hepatocyte sample analysis, P-gp substrate context, Phase I MetID, and quantitative LC-MS/MS.

Phase I MetID →

Irinotecan Is a Prodrug and Phase II Problem

Irinotecan is analytically distinct from the other compounds in this page. The workflow must account for CES-mediated activation and UGT1A1-linked Phase II metabolism rather than only parent-drug exposure.

Our responseParent-to-active analyte relationships, CES activation, UGT1A1-related glucuronidation, microsome / hepatocyte model selection, and MetID-based pathway interpretation.

Biotransformation Support →

DDI Risk Comes from Multiple Mechanisms

For this class, DDI risk can involve CYP metabolism, P-gp substrate behavior, Phase II clearance, or pathway-specific activation. One parent-drug readout can miss the mechanism behind exposure changes.

Our responseIntegrated CYP, transporter, activation, and Phase II metabolism context with LC-MS/MS quantification and metabolite profiling aligned to the research question.

DDI Risk Assessment →

One Panel Must Respect Compound-Specific Pathways

Doxorubicin, epirubicin, etoposide, and irinotecan are all topoisomerase inhibitor-related compounds, but their analytical routes differ substantially.

Our responseCustom panels with compound-specific extraction, chromatographic selectivity, metabolite-aware transitions, pathway-based calibration planning, and DDI-aware reporting.

Custom Panels →

Focused Service Paths

Four Practical Routes for Topoisomerase Inhibitor Studies

Instead of treating topoisomerase inhibitors as one uniform cytotoxic chemotherapy group, the analytical route should be selected according to the study objective: parent-drug quantification, CYP-mediated Phase I metabolism, P-gp-related disposition, CES-mediated activation, UGT1A1-related Phase II metabolism, DDI risk assessment, or custom oncology panel development.

Parent Topoisomerase Inhibitor Quantification

For studies that require doxorubicin, epirubicin, etoposide, irinotecan, or related topoisomerase inhibitor concentration data in biological matrices.

Parent-drug exposure studies
Plasma / serum bioanalysis
Tissue or cell lysate quantification
Matrix-specific LC-MS/MS setup

LC-MS/MS Drug Quantification →

CYP-Mediated Phase I MetID and DDI Risk

For studies where CYP2D6, CYP3A4, or Phase I metabolite formation defines the topoisomerase inhibitor readout.

Doxorubicin / epirubicin CYP2D6 and CYP3A4 studies
Etoposide CYP3A4 workflows
Phase I MetID
CYP-linked DDI risk interpretation

Metabolite Identification →

Prodrug Activation and Phase II Metabolism

For studies where CES activation, UGT1A1 glucuronidation, or parent-to-active analyte relationships define the analytical workflow.

Irinotecan CES-mediated activation
UGT1A1-related Phase II metabolism
Prodrug activation workflows
Microsome / hepatocyte model interpretation

Drug Metabolism & Biotransformation →

Custom Topoisomerase Inhibitor Panels

For studies involving multiple anthracyclines, etoposide, irinotecan, combination oncology panels, matrix comparison, or multi-analyte LC-MS/MS development.

Doxorubicin / epirubicin comparison panels
Etoposide / irinotecan panel development
Oncology multi-analyte LC-MS/MS
Pathway-aware reporting across Phase I and Phase II routes

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Topoisomerase Inhibitor?

If you are working with an anthracycline, podophyllotoxin derivative, camptothecin analog, prodrug, CYP2D6 / CYP3A4 metabolism question, CES activation pathway, UGT1A1-related Phase II workflow, P-gp substrate question, DDI risk study, or multi-analyte oncology panel, a standard parent-drug LC-MS/MS method may not be enough.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows for topoisomerase inhibitor research by defining the matrix type, expected concentration range, CYP pathway, transporter context, activation requirement, Phase II metabolism concern, MetID objective, DDI risk question, and panel compatibility before method development begins.

Target compound and analyte behavior

Matrix and expected concentration range

CYP2D6 / CYP3A4 pathway concern

P-gp or transporter context

CES / UGT1A1 pathway needs

DDI risk or panel workflow requirements